ADAR1's Private Funds Hold 5.2% Of Aura Biosciences' Common Shares

The investment adviser and its sole manager reported the same fund-held position and certified that it was held without a control purpose.

Share
ADAR1's Private Funds Hold 5.2% Of Aura Biosciences' Common Shares

Private funds managed by ADAR1 Capital Management, an investment adviser, held a 5.2% stake in Aura Biosciences, which develops precision cancer therapies intended to preserve organ function. ADAR1 reported the position as of September 30 in a passive ownership disclosure filed Monday, certifying that the shares were held without a purpose of changing or influencing Aura's control.

One Fund Position, Shared Voting Power

The funds directly owned 5,385,879 common shares. ADAR1 and Daniel Schneeberger, its sole manager, each reported indirect beneficial ownership — shares attributed to them through their relationship with the funds.

Both reported shared voting authority over that position. Their ownership entries cover the same fund-held shares.

The ownership percentage uses Aura's 103,950,771 common shares outstanding as of September 30, 2026. Aura reported that count in its quarterly report filed November 9, 2026.

ADAR1 and Schneeberger certified that the securities were bought and held as part of their ordinary business activities. The certification also covers participation in transactions intended to change or influence control.

Bel-Sar Leads Aura's Cancer Pipeline

Aura is a clinical-stage biotechnology company with no approved products. Its initial development focus is cancers affecting the eyes and urinary system.

Its lead candidate, bel-sar, combines a modified human papilloma virus protein shell with molecules activated by light. Those molecules kill tumor cells when switched on, forming the basis of a treatment designed to preserve organ function.

Bel-sar is in a global late-stage trial for early choroidal melanoma, a rare eye cancer. Aura says more than 11,000 patients receive that diagnosis annually across the United States and Europe.

The candidate is also being studied for cancers that spread to the choroid, cancers on the eye's surface and non-muscle-invasive bladder cancer. Aura's market value was $740 million as of Monday at 10:12 p.m. ET.

Sources

More on Aura Biosciences

All Aura Biosciences (AURA) coverage →